Alaunos Therapeutics (TCRT) Stock Price, News & Analysis

Company Overview

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

Key Stats

• Today's Range: $1.95 to $2.04
• 50-Day Range: $1.64 to $2.81
• 52-Week Range: $1.63 to $32.85
• Volume: 9,699 shs
• Average Volume: 17,956 shs
• Market Capitalization: $3.14 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TCRT Stock Analysis - Frequently Asked Questions

How have TCRT shares performed this year?

Alaunos Therapeutics' stock was trading at $10.6050 at the beginning of the year. Since then, TCRT shares have decreased by 81.5% and is now trading at $1.96.
View the best growth stocks for 2024 here.

How were Alaunos Therapeutics' earnings last quarter?

Alaunos Therapeutics, Inc. (NASDAQ:TCRT) posted its quarterly earnings data on Tuesday, November, 14th. The company reported ($6.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($4.50) by $1.50.

When did Alaunos Therapeutics' stock split?

Alaunos Therapeutics's stock reverse split on the morning of Thursday, July 18th 2024. The 1-10 reverse split was announced on Thursday, July 18th 2024. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 18th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Alaunos Therapeutics' major shareholders?

Top institutional shareholders of Alaunos Therapeutics include MSD Partners L.P. (6.31%).
View institutional ownership trends.

How do I buy shares of Alaunos Therapeutics?

Shares of TCRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Alaunos Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Alaunos Therapeutics investors own include Waste Connections (WCN), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), AUO (AUOTY), DiamondRock Hospitality (DRH), American Water Works (AWK) and Triple Flag Precious Metals (TFPM).

Company Calendar

• Last Earnings: 11/14/2023
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TCRT
• CUSIP: N/A
• CIK: 1107421
• Web: www.alaunos.com
• Phone: (346) 355-4099
• Fax: 617-241-2855
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-35,140,000.00
• Net Margins: N/A
• Pretax Margin: -196,349.98%
• Return on Equity: -267.77%
• Return on Assets: -209.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.30
• Quick Ratio: 4.30

Sales & Book Value

• Annual Sales: $7,000.00
• Price / Sales: 448.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.93 per share
• Price / Book: 0.50

Miscellaneous

• Outstanding Shares: 1,601,000
• Free Float: 1,519,000
• Market Cap: $3.14 million
• Optionable: Optionable
• Beta: -0.45